Acid suppression: Optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome (Q56387193)

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Reciprocal regulation of antral gastrin and somatostatin gene expression by omeprazole-induced achlorhydria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effects of calcitonin gene-related peptide on somatostatin and gastrin gene expression in rat antrum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Antral G-cell and D-cell numbers in Helicobacter pylori infection: effect of H. pylori eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Gastrin and somatostatin in Helicobacter pylori infected antral mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Impaired proximal duodenal mucosal bicarbonate secretion in patients with duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Nonsteroidal anti-inflammatory drugs and peptic ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Meta-analysis of risk factors for peptic ulcer. Nonsteroidal antiinflammatory drugs, Helicobacter pylori, and smoking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Natural History and Surgical Dilemma of "Stress" Gastric Bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Molecular cloning of a gene encoding the histamine H2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Definition and antagonism of histamine H 2 -receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Histamine secretion from rat enterochromaffinlike cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Gastrin receptors on isolated canine parietal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Expression cloning and characterization of the canine parietal cell gastrin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effects of gastrin on cytosolic free Ca2+ in individual, acid-secreting rat parietal cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

beta-subunit assembly is essential for the correct packing and the stable membrane insertion of the H,K-ATPase alpha-subunit.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Regions of association between the alpha and the beta subunit of the gastric H,K-ATPase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The site of action of pantoprazole in the gastric H+/K(+)-ATPase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Influence of the stimulation state of the parietal cells on the inhibitory effect of omeprazole on gastric acid secretion in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Parasitism by the "slow" bacterium Helicobacter pylori leads to altered gastric homeostasis and neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Healing of duodenal ulcer with an antacid regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Ranitidine and cimetidine in the healing of duodenal ulcer: meta-analysis of comparative clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A multicenter, double-blind, randomized, placebo-controlled comparison of nocturnal and twice-a-day famotidine in the treatment of active duodenal ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Omeprazole. Overview and opinion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Costs of duodenal ulcer therapy with antibiotics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Cimetidine for peptic ulcer in patients with arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The influence of cimetidine on peptic ulcer in patients with arthritis taking anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Resistance to medical therapy of gastric ulcers in rheumatic disease patients taking aspirin. A double-blind study with cimetidine and follow-up.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Cyclooxygenase 2 selective inhibitors: panacea or flash in the pan?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Interrelationships between Helicobacter pylori infection, nonsteroidal antiinflammatory drugs and gastroduodenal disease. A prospective study in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Surgery to cure the Zollinger-Ellison syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Zollinger-Ellison syndrome. Current concepts in diagnosis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Cimetidine 800 mg twice daily for healing erosions and ulcers in gastroesophageal reflux disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A comparison of five maintenance therapies for reflux esophagitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effect of antireflux operation on Barrett's mucosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Dihydroxy bile acids activate the transcription of cyclooxygenase-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Proximal esophageal pH-metry in patients with 'reflux laryngitis'

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Twenty-four-hour esophageal pH monitoring: the most useful test for evaluating noncardiac chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Opposing time trends of peptic ulcer and reflux disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Optimal therapy for stress gastritis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prevention of stress ulcer bleeding: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Current guidelines on stress ulcer prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Does antacid prophylaxis prevent upper gastrointestinal bleeding in critically ill patients?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Cimetidine and antacid prophylaxis of acute upper gastrointestinal bleeding in high risk patients. Controlled, randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Antacid titration in the prevention of acute gastrointestinal bleeding: a controlled, randomized trial in 100 critically ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Serum aluminium levels of intensive care patients treated with two different antacids for prevention of stress ulceration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Effect of sucralfate on absorption of norfloxacin and ofloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Changing perspectives of stress gastritis prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prophylactic therapy for stress ulcer bleeding: a reappraisal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Comparison of two intravenous ranitidine regimens in a homogeneous population of intensive care unit patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients: results of a prospective, randomized, crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion. A comparison of relative efficacy and cost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Comparison of omeprazole and ranitidine for stress ulcer prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Inhibitory effects of intravenous lansoprazole on gastric acid hypersecretion in patients with postoperative stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Aspiration of gastric bacteria in antacid-treated patients: a frequent cause of postoperative colonisation of the airway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Nosocomial Pneumonia in Intubated Patients Given Sucralfate as Compared with Antacids or Histamine Type 2 Blockers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Stress ulcer prophylaxis: gastrointestinal bleeding and nosocomial pneumonia. Best evidence synthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Risk of acute stress bleeding and nosocomial pneumonia in ventilated intensive care unit patients: sucralfate versus antacids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Antacid versus sucralfate in preventing acute gastrointestinal bleeding. A randomized trial in 100 critically ill patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Sucralfate suspension versus titrated antacid for the prevention of acute stress-related gastrointestinal hemorrhage in critically ill patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A comparison of omeprazole and placebo for bleeding peptic ulcer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Cimetidine for severe gastroduodenal haemorrhage: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Controlled trial of medical therapy for active upper gastrointestinal bleeding and prevention of rebleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Clot lysis by gastric juice: an in vitro study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

American Gastroenterological Association medical position statement: evaluation of dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

AGA technical review: evaluation of dyspepsia. American Gastroenterological Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Challenges in managing dyspepsia in general practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

Total 24-hour gastric acid secretion in patients with duodenal ulcer. Comparison with normal subjects and effects of cimetidine and parietal cell vagotomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

The continuing development of gastric acid pump inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

Clinical efficacy of pantoprazole compared with ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

Healing and relapse of severe peptic esophagitis after treatment with omeprazole

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021

Therapy of critically ill postoperative patients based on outcome prediction and prospective clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0016-5085%2800%2970004-7

7 January 2021